Company intelligence / Profile preview

Cimab

Havana, Havana, Cubacimab.cu ↗

Ownership: Private
Development stage: Other

Overview

Cimab has developed and marketed several monoclonal antibodies and recombinant proteins. Its lead products include nimotuzumab ("cimaher"), which is used for various cancers. The company also offers therapeutic vaccines such as cimavax and vaxira. Products are distributed internationally across Latin America, Asia, Africa, and the Middle East.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyRecombinant proteinVaccine (therapeutic)
Industry: Biotech

Partnerships

International distributors (Thailand, Singapore, Cuba, Jordan, Syria, Tunisia, Algeria, Peru, Bolivia)

Beyond the preview

Go deeper on Cimab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cimab.